M&A, drug prices and regulators: what lies ahead in 2019?

Predicting a year in pharma is difficult at the best of times, but in an era of enormous uncertainty – with politics in established markets as impulsive as it is divisive – it's hard to know what drugmakers will have to deal with in 2019, and how their strategies will play out.

The Pharma Letter has taken a look at three major topics across the drug sector, considering what might lie ahead in the year to come.

M&A activity